SCHEMBL4919350

SCHEMBL4919350

COc1ccc(-n2ncc3c(Nc4ccccc4NC(=O)c4cccc(C(F)(F)F)c4)ncnc32)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.54
MAPK1 P28482 3/20 0.54
GAA P10253 2/20 0.54
HSD17B10 Q99714 2/20 0.54
HTT P42858 1/20 0.54
SMN1; SMN2 Q16637 4/20 0.54
NPC1 O15118 4/20 0.54
RAB9A P51151 4/20 0.54
ALDH1A1 P00352 3/20 0.54
KDM4E B2RXH2 3/20 0.54
KMT2A Q03164 3/20 0.54
MEN1 O00255 2/20 0.54
MAPK14 Q16539 6/20 0.53
LMNA P02545 3/20 0.51
TP53 P04637 2/20 0.51
THRB P10828 1/20 0.51
KDR P35968 1/20 0.49
DYRK3 O43781 1/20 0.49
LCK P06239 1/20 0.49
CSF1R P07333 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4755211 0.90 MAPT (0.62) MAPTMAPK1GAAHSD17B10SMN1; SMN2
SCHEMBL4187241 0.89 MAPK14 (0.57) MAPTGAASMN1; SMN2NPC1RAB9A
SCHEMBL4697666 0.89 PIP4K2A (0.53) MAPTMAPK1GAAHSD17B10HTT
SCHEMBL4917652 0.88 MAPT (0.62) MAPTMAPK1GAAHSD17B10SMN1; SMN2
SCHEMBL4789574 0.86 MAPK14 (0.63) MAPTMAPK1GAAHSD17B10SMN1; SMN2
SCHEMBL4699408 0.86 MAPT (0.53) MAPTMAPK1GAAHSD17B10HTT
SCHEMBL4917379 0.85 MAPT (0.62) MAPTGAAHSD17B10SMN1; SMN2NPC1
SCHEMBL4701650 0.80 MAPK14 (0.59) MAPTMAPK14LMNATP53THRB
SCHEMBL4751792 0.80 MAPK14 (0.58) MAPTMAPK14LMNATP53THRB
SCHEMBL4699789 0.80 LMNA (0.59) MAPTMAPK14LMNATP53THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275054-A1 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors HOLZER PHILIPP 2008-11-06 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275054-A1 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors EPHB3, EPHB2, EPHB1 MAPT 2142/4885MAPK1 205/4885GAA 4701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.